PNC Financial Services Group
DRUG

PNC Financial Services Group’s Bright Minds Biosciences DRUG Stock Holding History

PNC Financial Services Group’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$546 – 5197
2025
Q3 		$546 Buy
+9
New +$349 ﹤0.01% 4787

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PNC Financial Services Group's DRUG Position: Q4 2025 in Review

PNC Financial Services Group sold out of Bright Minds Biosciences (DRUG) in Q4 2025, closing a stake of 9 shares — an estimated $546 sold.

PNC Financial Services Group first reported a position in DRUG in Q3 2025 and held it in 1 quarter. The position peaked at $546 in Q3 2025. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • PNC Financial Services Group reported no remaining Bright Minds Biosciences position as of Q4 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 9 Bright Minds Biosciences shares in Q4 2025, an estimated $546.
  • PNC Financial Services Group first reported a position in Bright Minds Biosciences in Q3 2025 and held it in 1 quarter.
  • PNC Financial Services Group's Bright Minds Biosciences position peaked at $546 in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.